Talphera (NASDAQ:TLPH) Stock Price Down 7.1% – Time to Sell?

Talphera, Inc. (NASDAQ:TLPHGet Free Report)’s stock price fell 7.1% during mid-day trading on Wednesday . The company traded as low as $0.71 and last traded at $0.72. 76,125 shares traded hands during trading, a decline of 16% from the average session volume of 90,133 shares. The stock had previously closed at $0.77.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TLPH shares. Maxim Group upgraded Talphera to a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Talphera in a report on Friday, August 16th.

Get Our Latest Research Report on Talphera

Talphera Trading Down 7.1 %

The business has a fifty day simple moving average of $0.84 and a two-hundred day simple moving average of $0.90. The company has a market cap of $12.18 million, a PE ratio of -1.04 and a beta of 0.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in shares of Talphera during the 2nd quarter worth $1,773,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Talphera during the 2nd quarter worth $64,000. Finally, Rosalind Advisors Inc. purchased a new position in shares of Talphera during the 3rd quarter worth $650,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

(Get Free Report)

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

Further Reading

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.